{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:49:34Z","timestamp":1773190174550,"version":"3.50.1"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"\nBackground<\/jats:title>\nThe World Health Organization (WHO) recommended cryptococcal antigen (CrAg) screening for people presenting with advanced HIV disease (AHD) and for those with positive CrAg without evidence of meningitis to initiate preemptive antifungal medication. Data on the implementation of WHO recommendations regarding CrAg screening is limited. We estimated pooled prevalence of CrAg screening uptake, cryptococcal antigenemia, lumbar puncture, cryptococcal meningitis and initiation of preemptive antifungal medication from available eligible published studies conducted in Africa.<\/jats:p>\n<\/jats:sec>\n\nMethods<\/jats:title>\nPubMed, Cochrane Library and Embase were searched for articles published between January 2011 and December 2023. CrAg uptake was defined as percentage of eligible people (CD4 \u2264 200 cells\/mm3<\/jats:sup> or WHO stage III\/IV) who received cryptococcal antigen testing. Stratified analysis to compare uptake and cryptococcal antigenemia between studies that involved multiple vs single sites was performed. Using random effects models, we computed the pooled estimate of CrAg screening uptake, cryptococcal antigenemia, lumbar puncture, cryptococcal meningitis, preemptive antifungals treatment and 95% confidence intervals (CIs).<\/jats:p>\n<\/jats:sec>\n\nResults<\/jats:title>\nTen studies with 18,820 individuals with AHD were analyzed. Overall, the pooled estimate of CrAg screening uptake was 57.1% (95% CI: 41.4\u201372.7). CrAg screening uptake was significantly lower among studies that involved multiple sites compared to those that involved single site, (47.3% vs 73.3%; p<0.001). Overall, the pooled prevalence of cryptococcal antigenemia was 9.6% (95% CI:6.4\u201312.9). Cryptococcal antigenemia was significantly lower among studies that involved multiple sites compared to those that involved single site, (9.1% vs 10.4%; p<0.001). Among those who tested positive for CrAg, 84.6% (95% CI: 54.1\u201399.0) received preemptive antifungal treatment, though nearly 25% did not undergo lumbar puncture, highlighting gaps in diagnostic follow-up. Six studies evaluated CrAg positive patients with lumbar puncture and the overall prevalence of lumbar puncture was 74.9% (48.0\u201394.8). The overall prevalence of cryptococcal meningitis was 58.1% (46.6\u201369.6).<\/jats:p>\n<\/jats:sec>\n\nConclusions<\/jats:title>\nNot screening for CrAg among people with AHD and failure to initiate antifungal medications among eligible patients with cryptococcal antigenemia presents a significant missed opportunity. Emphasis on improving CrAg screening is critical given its proven cost-effective benefits.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0313453","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T18:32:36Z","timestamp":1737743556000},"page":"e0313453","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Systematic review on the compliance of WHO guidelines in the management of patients with advanced HIV disease in Africa: The case of cryptococcal antigen screening"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0895-5248","authenticated-orcid":true,"given":"Zuhura Mbwana","family":"Ally","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jackline Vicent","family":"Mbishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariam Salim","family":"Mbwana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafidha Mhando","family":"Bakari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swalehe Mustafa","family":"Salim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zarin Nudar","family":"Rodoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhidin Ibrahim","family":"Hundisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca Mesfin","family":"Sileshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biruk Demisse","family":"Ayalew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahma","family":"Musoke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Moshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousef Elias","family":"Fakhoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haji Mbwana","family":"Ally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Habib Omari","family":"Ramadhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"issue":"6","key":"pone.0313453.ref001","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1086\/605500","article-title":"Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort","volume":"49","author":"B Castelnuovo","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"12","key":"pone.0313453.ref002","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/S1473-3099(22)00499-6","article-title":"The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis","volume":"22","author":"R Rajasingham","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"pone.0313453.ref003","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","article-title":"Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis","volume":"17","author":"R Rajasingham","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pone.0313453.ref004","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12879-020-4798-1","article-title":"Cryptococcal antigenemia is associated with meningitis or death in HIV-infected adults with CD4 100\u2013200 cells\/mm(3).","volume":"20","author":"J Wykowski","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"suppl_2","key":"pone.0313453.ref005","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1093\/cid\/cix1143","article-title":"CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis","volume":"66","author":"N Ford","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pone.0313453.ref006","doi-asserted-by":"crossref","first-page":"e0158986","DOI":"10.1371\/journal.pone.0158986","article-title":"Screening HIV-Infected Patients with Low CD4 Counts for Cryptococcal Antigenemia prior to Initiation of Antiretroviral Therapy: Cost Effectiveness of Alternative Screening Strategies in South Africa.","volume":"11","author":"BA Larson","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"pone.0313453.ref007","doi-asserted-by":"crossref","first-page":"e0210105","DOI":"10.1371\/journal.pone.0210105","article-title":"Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis.","volume":"14","author":"R Rajasingham","year":"2019","journal-title":"PLoS One"},{"issue":"7","key":"pone.0313453.ref008","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1086\/597262","article-title":"Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa","volume":"48","author":"JN Jarvis","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pone.0313453.ref009","doi-asserted-by":"crossref","DOI":"10.1093\/mmy\/myab078","article-title":"Cost-effectiveness of single-dose AmBisome pre-emptive treatment for the prevention of cryptococcal meningitis in African low and middle-income countries","volume":"60","author":"R Rajasingham","year":"2022","journal-title":"Med Mycol"},{"issue":"1","key":"pone.0313453.ref010","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12879-020-05126-z","article-title":"The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts <\u2009200 cells\/\u03bcL: evidence based on a meta-analysis.","volume":"20","author":"Y Li","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"4","key":"pone.0313453.ref011","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/cid\/ciy567","article-title":"Impact of Routine Cryptococcal Antigen Screening and Targeted Preemptive Fluconazole Therapy in Antiretroviral-naive Human Immunodeficiency Virus-infected Adults With CD4 Cell Counts <100\/\u03bcL: A Systematic Review and Meta-analysis","volume":"68","author":"E Temfack","year":"2019","journal-title":"Clin Infect Dis"},{"key":"pone.0313453.ref012","volume-title":"Guidelines for the Diagnosis, Prevention, and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children, March 2018.","author":"World Health Organization","year":"2018"},{"issue":"3","key":"pone.0313453.ref013","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s40121-021-00451-5","article-title":"Screening for Cryptococcal Antigenemia and Burden of Cryptococcosis at the Time of HIV Diagnosis: A Retrospective Multicenter Study.","volume":"10","author":"SH Huang","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"4","key":"pone.0313453.ref014","doi-asserted-by":"crossref","first-page":"e0214739","DOI":"10.1371\/journal.pone.0214739","article-title":"Lessons learned: Retrospective assessment of outcomes and management of patients with advanced HIV disease in a semi-urban polyclinic in Epworth, Zimbabwe.","volume":"14","author":"S Blankley","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"pone.0313453.ref015","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/tmi.12067","article-title":"The impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in Kenya.","volume":"18","author":"AC Meyer","year":"2013","journal-title":"Trop Med Int Health"},{"issue":"2","key":"pone.0313453.ref016","doi-asserted-by":"crossref","first-page":"ofab010","DOI":"10.1093\/ofid\/ofab010","article-title":"Cryptococcal Antigen Screening Among Antiretroviral Therapy-Experienced People With HIV With Viral Load Nonsuppression in Rural Uganda.","volume":"8","author":"JB Baluku","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"pone.0313453.ref017","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12981-022-00433-8","article-title":"Advanced HIV disease management practices within inpatient medicine units at a referral hospital in Zambia: a retrospective chart review","volume":"19","author":"N Mbewe","year":"2022","journal-title":"AIDS Res Ther"},{"issue":"1","key":"pone.0313453.ref018","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5334\/aogh.3532","article-title":"Implementing Advanced HIV Disease Care for Inpatients in a Referral Hospital in Malawi\u2014Demand, Results and Cost Implications.","volume":"88","author":"T Heller","year":"2022","journal-title":"Ann Glob Health"},{"issue":"1","key":"pone.0313453.ref019","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12913-022-07624-z","article-title":"Evaluation of the initial 12\u2009months of a routine cryptococcal antigen screening program in reduction of HIV-associated cryptococcal meningitis in Uganda.","volume":"22","author":"K Enock","year":"2022","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"pone.0313453.ref020","doi-asserted-by":"crossref","DOI":"10.1093\/mmy\/myac013","article-title":"Determinants of cryptococcal antigen (CrAg) screening uptake in Kampala, Uganda: An assessment of health center characteristics.","volume":"60","author":"D Srishyla","year":"2022","journal-title":"Med Mycol"},{"issue":"10","key":"pone.0313453.ref021","doi-asserted-by":"crossref","first-page":"e0292660","DOI":"10.1371\/journal.pone.0292660","article-title":"Rapid antiretroviral therapy initiation in patients with advanced HIV disease: 6-month outcomes of an observational cohort evaluation in Lesotho.","volume":"18","author":"A Tiam","year":"2023","journal-title":"PLoS One"},{"issue":"2","key":"pone.0313453.ref022","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1097\/QAI.0000000000000976","article-title":"Implementation and Operational Research: Evaluation of a Public-Sector, Provider-Initiated Cryptococcal Antigen Screening and Treatment Program, Western Cape, South Africa.","volume":"72","author":"S Vallabhaneni","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"pone.0313453.ref023","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/QAI.0000000000002717","article-title":"Laboratory Reflex and Clinic-Based Point-of-Care Cryptococcal Antigen Screening for Preventing Meningitis and Mortality Among People Living With HIV.","volume":"87","author":"PK Drain","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0313453.ref024","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"MJ Page","year":"2021","journal-title":"Bmj"},{"issue":"6","key":"pone.0313453.ref025","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/emermed-2020-209567","article-title":"Population, Intervention, Comparison, Outcomes and Study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews.","volume":"37","author":"M Amir-Behghadami","year":"2020","journal-title":"Emerg Med J"},{"key":"pone.0313453.ref026","unstructured":"National Institute for Health. Study Quality Assessment Tools. Available at: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"issue":"4","key":"pone.0313453.ref027","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence\u2014study limitations (risk of bias).","volume":"64","author":"GH Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"pone.0313453.ref028","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence\u2014inconsistency","volume":"64","author":"GH Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"pone.0313453.ref029","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence\u2014imprecision.","volume":"64","author":"GH Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"pone.0313453.ref030","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","article-title":"GRADE guidelines: 8. Rating the quality of evidence\u2014indirectness.","volume":"64","author":"GH Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"pone.0313453.ref031","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence\u2014publication bias","volume":"64","author":"GH Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"pone.0313453.ref032","unstructured":"R Core Team R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Available at: https:\/\/www.r-project.org\/. Accessed 10 May."},{"issue":"19","key":"pone.0313453.ref033","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.2832","article-title":"Chi-squared and Fisher-Irwin tests of two-by-two tables with small sample recommendations.","volume":"26","author":"I Campbell","year":"2007","journal-title":"Stat Med"},{"issue":"7414","key":"pone.0313453.ref034","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"JP Higgins","year":"2003","journal-title":"Bmj"},{"issue":"5","key":"pone.0313453.ref035","first-page":"2","article-title":"Cryptococcal antigenemia in HIV-infected adults in the African cohort study","volume":"97","author":"J. Sing\u2019oei VO","year":"2017","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"10","key":"pone.0313453.ref036","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/cid\/ciaa356","article-title":"Prevalence and Sequelae of Cryptococcal Antigenemia in Antiretroviral Therapy-Experienced Populations: An Evaluation of Reflex Cryptococcal Antigen Screening in Botswana","volume":"72","author":"WJ Hurt","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pone.0313453.ref037","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12879-022-07224-6","article-title":"Implementation of tuberculosis and cryptococcal meningitis rapid diagnostic tests amongst patients with advanced HIV at Kamuzu Central Hospital, Malawi, 2016\u20132017.","volume":"22","author":"C Kanyama","year":"2022","journal-title":"BMC Infect Dis"},{"issue":"9","key":"pone.0313453.ref038","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1097\/QAD.0b013e32832be0fc","article-title":"High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out","volume":"23","author":"JN Jarvis","year":"2009","journal-title":"Aids"},{"issue":"9","key":"pone.0313453.ref039","doi-asserted-by":"crossref","DOI":"10.2217\/fvl.13.71","article-title":"Primary prophylaxis for cryptococcal meningitis and impact on mortality in HIV: a systematic review and meta-analysis.","volume":"8","author":"R Ssekitoleko","year":"2013","journal-title":"Future Virol"},{"issue":"7","key":"pone.0313453.ref040","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/cid\/cix036","article-title":"Primary Prophylaxis for Cryptococcosis With Fluconazole in Human Immunodeficiency Virus-Infected Patients With CD4 T-Cell Counts <100 Cells\/\u03bcL and Receiving Antiretroviral Therapy","volume":"64","author":"S Sungkanuparph","year":"2017","journal-title":"Clin Infect Dis"},{"key":"pone.0313453.ref041","volume-title":"StatPearls","author":"LA Jane","year":"2024"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0313453","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T18:32:59Z","timestamp":1737743579000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0313453"}},"subtitle":[],"editor":[{"given":"Robert Jeffrey","family":"Edwards","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0313453","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]}}}